This article is for informational purposes only and does not constitute medical or legal advice. Cannabis laws vary by jurisdiction. Consult a healthcare provider before using cannabinoid products, especially if taking medications.
By CaliforniaCannabinoids Editorial Team | Last verified: July 2026
What Is Myrcene?
Myrcene (β-myrcene) is a naturally occurring hydrocarbon monoterpene with the molecular formula C₁₀H₁₆. It is the single most abundant terpene produced in cannabis, frequently comprising 40–65% of the total terpene content in many popular strains, particularly those with sedative or relaxing effects. Beyond cannabis, myrcene is found in significant concentrations in mango fruit, hops, basil, thyme, cardamom, lemongrass, and marjoram—making it one of the most widespread terpenes in nature.
In cannabis, myrcene is synthesized by the plant during the flowering stage as part of the secondary metabolite cascade. The terpene is produced in the trichomes alongside cannabinoids like THChref=”https://californiacannabinoids.com/delta-8-thc-ingredient/”>THC and CBD. Structurally, myrcene contains two isoprene units and is classified as a linear monoterpene (also called acyclic); this open structure distinguishes it from cyclic terpenes like limonene or pinene and influences its volatility, aroma diffusion, and biological activity.
The presence of myrcene in other commonly consumed plants—particularly mangoes and hops—has led to cultural associations between the terpene and relaxation. However, myrcene itself is not psychoactive. Instead, research suggests myrcene may modulate the effects of THC and other cannabinoids through the “entourage effect,” a hypothesis that whole-plant compounds work synergistically to produce effects greater than their individual contributions.
How Myrcene Works
Unlike THC or CBD, myrcene does not significantly bind to CB1 or CB2 cannabinoid receptors at physiological concentrations. Instead, its pharmacological activity operates through alternative pathways that are only partially understood.
Receptor and Channel Activity
Research indicates that myrcene may activate the TRPV3 ion channel, a heat and osmotic stress sensor expressed in skin, brain, and immune tissues. Activation of TRPV3 is associated with anti-inflammatory and analgesic (pain-relief) signaling. Additionally, myrcene shows weak affinity for CB2 receptors on immune and peripheral tissues, though the functional significance remains unclear at typical cannabis-consumption doses.
A pivotal hypothesis in cannabis pharmacology suggests that myrcene may increase the permeability of the blood-brain barrier, potentially allowing greater central nervous system penetration of THC and other cannabinoids. This mechanism, proposed in early literature but not definitively proven in humans, would explain why high-myrcene strains are subjectively reported as producing stronger or faster-onset effects despite similar THC content. This remains one of the most debated claims in cannabis science and requires rigorous clinical validation.
Metabolic Interactions
Myrcene is rapidly metabolized in the liver and plasma via oxidation and conjugation pathways. It does not significantly inhibit cytochrome P450 enzymes, distinguishing it from CBD, which is a potent CYP3A4 inhibitor. This means myrcene carries minimal risk of direct pharmacokinetic drug interactions, though animal studies suggest it may modestly enhance the absorption of lipophilic (fat-soluble) compounds due to its own lipophilic nature.
What the Research Shows
Research on myrcene is limited relative to major cannabinoids, but emerging preclinical and preliminary clinical evidence suggests several biological activities. Most studies are conducted in cell cultures or animal models; human clinical trials are sparse.
Anti-Inflammatory and Immunomodulation
Preclinical evidence in animal models suggests myrcene reduces pro-inflammatory cytokine production (TNF-α, IL-6) and suppresses NF-κB signaling, a key inflammatory pathway. A 2015 study in *Molecules* found that myrcene reduced LPS-induced inflammatory markers in mouse macrophages. However, no published human clinical trials confirm these effects at cannabis-relevant doses. Evidence Grade: Preclinical (animal/cell models only).
Analgesia (Pain Relief)
Mouse models of neuropathic and inflammatory pain show myrcene-mediated analgesia, possibly through TRPV3 activation and prostaglandin reduction. A 2013 study published in *Journal of Natural Products* reported myrcene analgesic effects comparable to aspirin in rodent pain tests. Critically, no peer-reviewed human pain trials exist. Anecdotal reports of pain relief from myrcene-rich cannabis strains cannot be separated from THC and CBD contributions. Evidence Grade: Preclinical.
Sleep and Sedation
Myrcene is often marketed as a “sedative terpene” based on the common cultural association between mangoes and relaxation, and between hops (which contain myrcene) and sleep-promoting beer. However, direct evidence for myrcene-induced sedation in humans is absent. Controlled studies in mice show modest sedative properties, but translation to humans at typical inhalation or ingestion doses remains unproven. Sleep effects attributed to myrcene-rich strains likely reflect THC, CBD, or other terpenes (linalool, beta-caryophyllene). Evidence Grade: Preclinical; clinical evidence lacking.
Muscle Relaxation
Animal studies suggest myrcene may enhance muscle relaxation through CNS depression pathways. One mouse model of muscle tension showed myrcene-mediated relaxation; however, this does not translate reliably to human efficacy claims without clinical confirmation. Evidence Grade: Preclinical.
Antioxidant Activity
In vitro (cell culture) studies demonstrate myrcene’s free-radical scavenging ability, but bioavailability and in vivo antioxidant efficacy in humans remain uncharacterized. Evidence Grade: In vitro only.
Delivery Methods and Bioavailability
Myrcene’s volatile nature and lipophilic properties influence how it is absorbed and retained in the body depending on delivery method.
Inhalation (Smoking/Vaping)
Myrcene has a boiling point of 167°C, making it volatile at cannabis smoking temperatures (150–200°C). Inhalation provides rapid onset (seconds to minutes) and efficient delivery of myrcene to the lungs and bloodstream. However, significant myrcene loss occurs during combustion; vaping at lower temperatures (160–180°C) preserves more myrcene than smoking. Duration of effect is typically 2–4 hours. Bioavailability is moderate to high but varies with individual lung physiology.
Oral Ingestion (Edibles)
When consumed in edibles, myrcene is absorbed through the gastrointestinal tract and undergoes first-pass hepatic metabolism. Onset is delayed (1–3 hours) compared to inhalation. Myrcene’s lipophilic nature means absorption is enhanced when consumed with fat (e.g., cannabis-infused oils or butter). Duration is extended to 4–8 hours or longer depending on stomach contents. Bioavailability via oral administration is lower than inhalation due to hepatic degradation and the blood-brain barrier limitation (though myrcene’s proposed role in enhancing BBB permeability remains speculative).
Topical Application
Myrcene in topical creams and salves penetrates the skin barrier and may accumulate in local tissues. Systemic absorption is minimal. Onset is gradual (15–30 minutes). Topical myrcene is used in cosmetics and massage products for its anti-inflammatory potential, though peer-reviewed clinical evidence in dermatology is limited.
Legal and Regulatory Status
Federal Status
Myrcene itself is not a controlled substance under federal law. As a terpene found in non-cannabis plants (mangoes, hops, basil) and widely used in food, cosmetics, and fragrances, it is classified as GRAS (Generally Recognized as Safe) by the FDA for flavoring applications. Cannabis products containing myrcene are subject to the same federal restrictions as cannabis itself: cannabis with >0.3% THC by dry weight is federally prohibited outside licensed cultivators in states with legal medical or adult-use programs.
California Status
California permits cannabis cultivation, testing, and sale in licensed retail dispensaries. Myrcene content is not regulated or restricted; however, California requires full cannabinoid and terpene profiling for all retail cannabis products. Products are tested for potency, pesticides, heavy metals, and microbial contaminants. Myrcene levels are reported but not subject to maximum-concentration caps (unlike some pesticides or residual solvents).
Broader Regulatory Context
CBD-dominant products and other hemp-derived cannabinoids may be sold federally under the 2018 Farm Bill if they contain <0.3% THC. Myrcene presence in these products is unrestricted. However, terpene-dominant products marketed as aromatherapy or therapeutic agents may face FDA scrutiny if they make unsubstantiated health claims without human clinical trial support.
Who Should Consider Myrcene-Rich Cannabis
Potential candidates: Individuals seeking cannabis strains associated with relaxation, sleep support, or anti-inflammatory effects may explore myrcene-dominant varieties. Users interested in understanding strain profiles and entourage effects may benefit from studying myrcene’s role. Those using cannabis for chronic pain or inflammation may find myrcene-rich strains worth trialing, though clinical evidence remains limited.
Practical note: Myrcene abundance is correlated (not causative) with relaxing effects in cannabis strains. High-myrcene strains often also contain high THC and complementary terpenes (linalool, caryophyllene), making it difficult to isolate myrcene’s individual contribution. Strain labels reporting myrcene concentration can guide selection but should not be the only factor in choosing cannabis.
Who Should Avoid or Exercise Caution
Pregnancy and breastfeeding: Cannabis use during pregnancy and lactation is not recommended due to THC’s established neurodevelopmental risks. Myrcene itself lacks specific pregnancy safety data, but myrcene-rich strains typically contain THC. Pregnant and breastfeeding individuals should consult healthcare providers before cannabis use.
Driving and operating machinery: Myrcene-rich strains, particularly when combined with THC, may impair motor coordination and reaction time due to cannabinoid effects. Users should avoid driving after consumption. Myrcene alone does not impair cognition, but it may potentiate THC’s effects.
Psychiatric vulnerability: High-THC cannabis, often associated with myrcene-dominant strains marketed as “heavy-hitting,” may increase psychotic symptoms in individuals with schizophrenia or bipolar disorder. Low-THC, myrcene-rich strains or myrcene as an isolated terpene may carry lower risk, but evidence is insufficient. Mental health history should inform strain selection.
Drug interaction caution: While myrcene itself does not inhibit CYP450 enzymes, myrcene-rich cannabis strains often contain THC and CBD. CBD is a potent CYP3A4 inhibitor and can increase plasma concentrations of medications metabolized by this enzyme (statins, immunosuppressants, antihistamines). Consult a pharmacist if using myrcene-rich cannabis alongside medications.
Safety and Side Effects
Myrcene-Specific Safety Profile
Myrcene has a favorable toxicity profile in preclinical studies. Acute oral LD50 (lethal dose) in rodents is >2000 mg/kg, indicating low systemic toxicity. Myrcene is GRAS-approved for food, suggesting a wide margin of safety at typical culinary and cosmetic concentrations.
At high concentrations (e.g., in isolated myrcene supplements), myrcene may cause dizziness, headache, or mild gastrointestinal upset, though these effects are poorly characterized in humans. No published human toxicology studies exist.
Interaction with THC and CBD
The primary safety concern with myrcene-rich cannabis is not myrcene itself but the cannabinoid profile. High-myrcene strains are statistically more likely to be high-THC, increasing the risk of acute intoxication, anxiety, or psychotic symptoms in sensitive individuals. THC, not myrcene, drives these effects.
If a myrcene-rich strain also contains significant CBD, the CBD’s CYP3A4 inhibition may increase plasma levels of co-administered medications (see above).
Cannabinoid Drug Interactions
Myrcene itself does not inhibit major cytochrome P450 enzymes and is not expected to cause direct pharmacokinetic drug interactions. However, THC is a weak CYP2C9 and CYP3A4 inhibitor, and CBD is a potent CYP3A4 inhibitor. Users taking medications metabolized by these enzymes should discuss cannabis use with their healthcare provider or pharmacist.
Allergenicity
Myrcene is a common fragrance allergen. Individuals with essential oil or fragrance allergies may experience contact dermatitis or respiratory sensitivity to myrcene-rich cannabis products, particularly if vaped. Topical cannabis products containing myrcene should be patch-tested before broad application.
Key Takeaway
Myrcene is the most abundant terpene in cannabis and is ubiquitous in nature, offering a strong safety profile and GRAS status outside of cannabis contexts. While preclinical research suggests anti-inflammatory, analgesic, and sedative properties, human clinical evidence is virtually absent. Myrcene likely contributes to the subjective effects and aroma of cannabis strains but should not be viewed as a bioactive “silver bullet” for pain, sleep, or inflammation. Its potential role in enhancing cannabinoid bioavailability remains speculative and unproven in humans.
For consumers, myrcene content on a strain label provides useful aromatics and flavor information and correlates with historical strain effects, but is not a substitute for understanding individual cannabinoid profiles (THC and CBD) and conducting personal trials under controlled conditions. Healthcare providers and patients should weight myrcene-rich strains’ effects primarily through their THC and CBD content and broader terpene profiles, reserving myrcene as a secondary descriptor rather than a primary therapeutic target.
Further reading: Complete Guide to Cannabis Terpenes | The Entourage Effect: Science and Skepticism | CBD Profile and Drug Interactions
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.